Mary C Zuniga1, Gayatri Raghuraman1, Elizabeth Hitchner1, Cornelia Weyand2, William Robinson2, Wei Zhou3. 1. Department of Vascular Surgery, VA Palo Alto Health Care System, Palo Alto, CA, USA. 2. Department of Vascular Surgery, VA Palo Alto Health Care System, Palo Alto, CA, USA; Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA, USA. 3. Division of Vascular Surgery, Department of Surgery, University of Arizona, Tucson, AZ, USA; Department of Vascular Surgery, Southern Arizona VA Health Care System, Tucson, AZ, USA. Electronic address: zhouw@email.arizona.edu.
Abstract
BACKGROUND AND AIMS: Resistin has been associated with atherosclerotic inflammation and cardiovascular complications. We and others have previously shown that PKC-epsilon (PKCε) is involved in resistin-induced smooth muscle cell (VSMC) dysfunction at a high pathological concentration. This study aimed to evaluate the role and potential pathways of resistin at a physiological concentration, in atherosclerosis-related inflammation. METHODS: Plasma from patients with atherosclerosis was analyzed for resistin concentration. Patients were divided into tertiles based on resistin levels and cytokines were compared between tertiles. Macrophages were then treated with resistin in the presence or absence of PKCε inhibitor and/or TLR4 blocking-antibody, and their inflammatory state was evaluated with ELISA, RT-PCR, immunocytochemistry, and Western blot. RESULTS: We observed significant associations between plasma resistin levels and TNF-α, IL-6, IL-12, MIP-1α, MIP-1β, and CD40L. Our in vitro analyses revealed that resistin activated PKCε via TLR4. This was followed by NF-kB activation and induction of a pro-inflammatory phenotype in macrophages, significantly upregulating CD40, downregulating CD206 and stimulating gene expression and secretion of the inflammatory cytokines, for which we found association in our plasma analysis. Resistin also induced persistent TRAM and CD40L upregulation up to 36 h after resistin treatment. PKCε and TLR4 inhibitors suppressed gene expression to levels similar to control, especially when used in combination. CONCLUSIONS: Resistin, at a physiological concentration, exacerbates the inflammatory response of macrophages. PKCε is a key upstream mediator in resistin-induced inflammation that may interact synergistically with TLR4 to promote NF-kB activation, while TRAM is an important signal. PKCε and TRAM may represent novel molecular targets for resistin-associated chronic atherosclerotic inflammation.
BACKGROUND AND AIMS: Resistin has been associated with atherosclerotic inflammation and cardiovascular complications. We and others have previously shown that PKC-epsilon (PKCε) is involved in resistin-induced smooth muscle cell (VSMC) dysfunction at a high pathological concentration. This study aimed to evaluate the role and potential pathways of resistin at a physiological concentration, in atherosclerosis-related inflammation. METHODS: Plasma from patients with atherosclerosis was analyzed for resistin concentration. Patients were divided into tertiles based on resistin levels and cytokines were compared between tertiles. Macrophages were then treated with resistin in the presence or absence of PKCε inhibitor and/or TLR4 blocking-antibody, and their inflammatory state was evaluated with ELISA, RT-PCR, immunocytochemistry, and Western blot. RESULTS: We observed significant associations between plasma resistin levels and TNF-α, IL-6, IL-12, MIP-1α, MIP-1β, and CD40L. Our in vitro analyses revealed that resistin activated PKCε via TLR4. This was followed by NF-kB activation and induction of a pro-inflammatory phenotype in macrophages, significantly upregulating CD40, downregulating CD206 and stimulating gene expression and secretion of the inflammatory cytokines, for which we found association in our plasma analysis. Resistin also induced persistent TRAM and CD40L upregulation up to 36 h after resistin treatment. PKCε and TLR4 inhibitors suppressed gene expression to levels similar to control, especially when used in combination. CONCLUSIONS:Resistin, at a physiological concentration, exacerbates the inflammatory response of macrophages. PKCε is a key upstream mediator in resistin-induced inflammation that may interact synergistically with TLR4 to promote NF-kB activation, while TRAM is an important signal. PKCε and TRAM may represent novel molecular targets for resistin-associated chronic atherosclerotic inflammation.
Authors: J Lauran Stöger; Marion J J Gijbels; Saskia van der Velden; Marco Manca; Chris M van der Loos; Erik A L Biessen; Mat J A P Daemen; Esther Lutgens; Menno P J de Winther Journal: Atherosclerosis Date: 2012-09-26 Impact factor: 5.162
Authors: Evan D Muse; David I Feldman; Michael J Blaha; Zeina A Dardari; Roger S Blumenthal; Matthew J Budoff; Khurram Nasir; Michael H Criqui; Mary Cushman; Robyn L McClelland; Matthew A Allison Journal: Atherosclerosis Date: 2014-12-23 Impact factor: 5.162
Authors: F Mach; U Schönbeck; G K Sukhova; T Bourcier; J Y Bonnefoy; J S Pober; P Libby Journal: Proc Natl Acad Sci U S A Date: 1997-03-04 Impact factor: 11.205
Authors: Rong-Ze Yang; Qing Huang; Aihua Xu; John C McLenithan; Jonathan A Eisen; Alan R Shuldiner; Serhan Alkan; Da-Wei Gong; Jonathan A Eison Journal: Biochem Biophys Res Commun Date: 2003-10-24 Impact factor: 3.575
Authors: Bashar Zeidan; Antigoni Manousopoulou; Diana J Garay-Baquero; Cory H White; Samantha E T Larkin; Kathleen N Potter; Theodoros I Roumeliotis; Evangelia K Papachristou; Ellen Copson; Ramsey I Cutress; Stephen A Beers; Diana Eccles; Paul A Townsend; Spiros D Garbis Journal: Breast Cancer Res Date: 2018-03-22 Impact factor: 6.466
Authors: Mary F O'Leary; Graham R Wallace; Edward T Davis; David P Murphy; Thomas Nicholson; Andrew J Bennett; Kostas Tsintzas; Simon W Jones Journal: Sci Rep Date: 2018-10-18 Impact factor: 4.379